KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Long-Term Investments (2016 - 2025)

Quest Diagnostics' Long-Term Investments history spans 12 years, with the latest figure at $136.0 million for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 10.57% year-over-year to $136.0 million; the TTM value through Dec 2025 reached $136.0 million, up 10.57%, while the annual FY2025 figure was $136.0 million, 10.57% up from the prior year.
  • Long-Term Investments for Q4 2025 was $136.0 million at Quest Diagnostics, down from $137.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $527.0 million in Q1 2021 and bottomed at $111.0 million in Q2 2021.
  • The 5-year median for Long-Term Investments is $134.5 million (2023), against an average of $152.6 million.
  • The largest annual shift saw Long-Term Investments tumbled 77.58% in 2021 before it soared 32.43% in 2022.
  • A 5-year view of Long-Term Investments shows it stood at $141.0 million in 2021, then dropped by 6.38% to $132.0 million in 2022, then increased by 2.27% to $135.0 million in 2023, then decreased by 8.89% to $123.0 million in 2024, then increased by 10.57% to $136.0 million in 2025.
  • Per Business Quant, the three most recent readings for DGX's Long-Term Investments are $136.0 million (Q4 2025), $137.0 million (Q3 2025), and $136.0 million (Q2 2025).